Spiro-Cyclic Amine Derivatives for S1P5 Selective Agonism

The patent introduces a novel chemical compound structure (spiro-cyclic amine derivative) with specific molecular parameters designed to optimize binding affinity to S1P5 receptors. The compound features a spiro-cyclic core structure with specific substituents (R1-R6 groups) that can be varied to fine-tune pharmacological properties, representing a parameter change approach to improve therapeutic effectiveness for cognitive disorders

The patent segments the therapeutic approach by targeting a specific receptor subtype (S1P5) within the broader S1P receptor family, rather than using non-selective agents. This segmentation allows for focused modulation of cognitive functions while minimizing off-target effects on cardiovascular and immunomodulatory systems, thereby expanding versatile treatment options

The patent applies local quality by designing a compound with selective affinity for the S1P5 receptor subtype, concentrating the pharmacological effect specifically at the cognitive neural circuits where S1P5 receptors are expressed. The molecular structure is optimized to interact preferentially with S1P5 binding sites in the brain, creating a localized therapeutic effect that spares cardiovascular and immune systems from unwanted activation

The spiro-cyclic amine derivative acts as a selective intermediary agent that mediates communication between the administered drug and the S1P5 receptor. This intermediary has been specifically designed with molecular features that facilitate binding to S1P5 while lacking the structural characteristics required for binding to S1P1, S1P2, or S1P3 receptors, thereby preventing activation of pathways leading to cardiovascular contraction or immunomodulation